A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
← catalyst calendarNCT07343960 · readout in 83 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
20estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-06 | actual | When the study began enrolling |
| Primary completion | 2026-11-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-11 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate Hepatic Impairment
Intervention
- Drug: Capivasertib — also filed as AZD5363
Primary outcomes
what the primary-completion date above is the date OFArea under concentration time curve from zero to infinity (AUCinf)
measured From Day 1 to Day 4
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
measured From Day 1 to Day 4
Maximum plasma drug concentration (Cmax)
measured From Day 1 to Day 4
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed